Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER-3
2014-003437-26Phase 3Completed
- Sponsor
- Clovis Oncology
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rociletinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Clovis Oncology. Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
rociletinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003437-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003437-26.